Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. Part 4: Heterocycles at C3
Yue, E.W., Dimeo, S.V., Higley, C.A., Markwalder, J.A., Burton, C.R., Benfield, P.A., Grafstrom, R.H., Cox, S., Muckelbauer, J.K., Smallwood, A., Chen, H., Chang, C.-H., Trainor, G.L., Seitz, S.P.(2004) Bioorg Med Chem Lett 14: 343-346
- PubMed: 14698155 
- DOI: https://doi.org/10.1016/j.bmcl.2003.11.008
- Primary Citation of Related Structures:  
2B52 - PubMed Abstract: 
New indeno[1,2-c]pyrazol-4-one cyclin dependent kinase inhibitors have been disclosed. The most promising compounds are nanomolar enzyme inhibitors with excellent activity against tumor cells. The most advanced compound retains cell culture activity even in the presence of human serum proteins. The most advanced compound did not kill the normal fibroblast line AG1523.
Organizational Affiliation: 
Bristol-Myers Squibb Company, Experimental Station, PO Box 80500, Wilmington, DE 19880-0500, USA. eddyyue@incyte.com